The last few decades have been dominated by the search for the perfect relaxant; in particular, an ultra-short-acting relaxant which does not depend upon plasma cholinesterases or liver metabolism for biodegradation. The perfect drug remains elusive but some interesting and useful drugs have been produced along the way.
It was the search for a replacement for suxamethonium that led indirectly to the development of atracurium. Professor John Stenlake 1 was working on several aspects of neuromuscular blockade at Strathclyde University in Glasgow in the 1950s. Coincidentally he was also responsible for the research into an alkaloid from the tubers of a Mediterranean plant. This alkaloid was a simple benzylisoquinoline quaternary salt and was found to degrade in mild alkali by Hofmann elimination, a process which normally requires a strong alkali and a high temperature. This discovery triggered the idea for a new muscle relaxant which would undergo Hofmann elimination at physiological pH and body temperature.
Professor Stenlake's objective was to synthesize a bisquaternary compound with competitive action, high potency and selectivity which was degraded by Hofmann elimination within the body at an appropriate rate. In retrospect these were very specific goals which one would imagine posed quite a challenge. Stenlake investigated four series of compounds and found a suitable candidate in the fourth series, only the eighteenth compound they had tested. 18A, as it was known, showed promising separation between vagal blocking and neuromuscular blocking doses and the challenge was then to increase its water solubility. Eventually it was presented as a besylate salt and produced for clinical testing as atracurium besylate, an aqueous solution of 10 mg/ml. It was clear that the compound was degraded by Hofmann elimination and then plasma hydrolysis but it was subsequently shown that complete absence of plasma cholinesterase did not slow degradation of atracurium.
Atracurium was first used clinically by Payne and Hughes in 1981 2 . They found it to be a satisfactory competitive neuromuscular blocker of intermediate duration with minimal cardiovascular side-effects. As its use became more widespread, it was noted that histamine release occurred in some patients but it appeared that most reactions were cutaneous without significant cardiovascular effects. As expected, it was found to be extremely useful in patients with impaired liver or renal function, the elderly and where infusions were required.
Atracurium is a mixture of ten stereoisomers in unequal but constant proportions. Eventually it was possible to separate these isomers and one was found to have twice the potency of the racemic mixture. This isomer had a similar duration of action and was eventually developed to become cisatracurium. To date, cisatracurium appears to cause less histamine release than atracurium.
Concomitant with these developments, Organon continued to experiment with derivatives of pancuronium and vecuronium. Two derivatives showed particular promise-Org 9426 and Org 9487. Org 9426 was clinically tested in the Netherlands by Wierda and colleagues 3 . They found that it was less potent than vecuronium but had a faster onset of neuromuscular blockade with good to excellent intubating conditions after 60 seconds. Duration of action and recovery were similar to vecuronium with no side-effects seen in their trial. This drug, rocuronium, was released in 1994 in the U.S. as Zemuron and elsewhere as Esmeron.
Org 9487, rapacuronium (Raplon) generated considerable excitement at the time of the phase III clinical trials in 1999. An editorial by Goulden and Hunter 4 in the April edition of the British Journal of Anaesthesia in that year asked, "Rapacuronium (Org 9487): do we have a replacement for succinylcholine?" They concluded that, in adequate dosage, rapacuronium was a rapidly acting drug with an onset time closer to succinylcholine than any other non-depolarizing drug. However they did have reservations. Intubating conditions were variable and it did not provide the consistent excellent conditions provided by suxamethonium. Recovery times were also variable, and although they could be modified with anticholinesterases, were not sufficiently short to be comparable with suxamethonium. The other concern about rapacuronium was that there were a number of reports of bronchospasm from the initial clinical trials.
Bronchospasm proved to be the biggest problem with rapacuronium. Following its release on to the market, reports of bronchospasm were frequent and life-threatening, especially in children and young adults. Bronchospasm was found to be more likely when the drug was injected rapidly, as in a rapid sequence induction. Since the drug was intended as a substitute for suxamethonium, this problem negated its usefulness. The drug was voluntarily withdrawn from the market in March 2001.
Several other relaxants, mivacurium, pipercuronium and doxacurium have been made available in recent years and the modern anaesthetist can select from a wide range of neuromuscular blocking agents. There is not yet a perfect relaxant but there is usually an appropriate drug for any given situation. Despite its many side-effects, suxamethonium remains the "gold standard" for a rapid sequence induction. Paul White concluded in an editorial in 2002, "The availability of a safe and cost-effective fast-onset, shortduration nondepolarizing NMBA would fill a long-standing void in the anaesthetist's armamentarium".
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